<DOC>
	<DOC>NCT02848326</DOC>
	<brief_summary>This study will evaluate the safety and tolerability of the following doses of AGN-241689: 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and will characterize the dose/response relationship.</brief_summary>
	<brief_title>Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral AGN-241689 in Episodic Migraine Prevention</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Has at least a 1year history of migraine with or without aura Age of the patient at the time of migraine onset &lt; 50 years History of 4 to 14 migraine/probable migraine headache days per month on average in the 3 months prior to Visit 1 in the Investigator's judgment Demonstrated compliance with ediary Has a history of migraine accompanied by diplopia or decreased level of consciousness, hemiplegic migraine, and retinal migraine Has a current diagnosis of chronic migraine, new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy Difficulty distinguishing migraine headache from other headaches Has a history of malignancy in the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer Has a history of gastric or small intestinal surgery, or has a disease that causes malabsorption Has a history of hepatitis within previous 6 months Usage of opioids or barbiturates &gt; 2 days/month, triptans or ergots ≥ 10 days/month, or simple analgesics (eg, aspirin, nonsteroidal antiinflammatory drugs [NSAIDs], acetaminophen) ≥ 15 days/month in the 3 months prior to Visit 1 Pregnant or nursing females</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>